Anticancer therapy as a pediatric pharmacodynamic paradigm.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Developmental Pharmacology and Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000457589PMID 2693007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer

  2004cited by this paper
• Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia

  2004cited by this paper
• Can severe vincristine neurotoxicity be prevented?

  2004cited by this paper
• Physician compliance and relapse rates of acute lymphoblastic leukemia in children

  1988cited by this paper
• The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia.

  1988cited by this paper
• Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.

  1988cited by this paper
• Pharmacokinetics of Anticancer Drugs in Children

  1987cited by this paper
• Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.

  1987cited by this paper
• Blood levels of chemotherapeutic agents and clinical outcome.

  1987cited by this paper
• Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

  1987cited by this paper
• Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children

  1987cited by this paper
• Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance

  1986cited by this paper
• Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.

  1986cited by this paper
• Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

  1986cited by this paper
• Dose-response is alive and well.

  1986cited by this paper
• Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

  1985cited by this paper
• Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia.

  1984cited by this paper
• Teniposide (VM26) disposition in children with leukemia.

  1984cited by this paper
• Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.

  1984cited by this paper
• Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.

  1984cited by this paper
• Methotrexate cerebrospinal fluid and serum concentrations after intermediate‐dose methotrexate infusion

  1983cited by this paper
• Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children.

  1983cited by this paper
• Test dose for predicting high‐dose methotrexate infusions

  1983cited by this paper
• Disposition of Intermediate-Dose Methotrexate in Children with Acute Lymphocytic Leukemia

  1982cited by this paper
• Effect of age and sex on theophylline clearance in young subjects.

  1982cited by this paper
• Oral theophylline dosage for the management of chronic asthma.

  1978cited by this paper
• Use of gentamicin serum levels to individualize therapy in children.

  1978cited by this paper
• Pharmacokinetics of theophylline in children with asthma.

  1976cited by this paper
• Pharmacokinetic analysis of the disposition of intravenous theophylline in young children.

  1976cited by this paper
• Drug dosage and remission duration in childhood lymphocytic leukemia

  1971cited by this paper
• DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN.

  1964cited by this paper

• The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment

  2004cites this paper
• Pharmacodynamics of cancer chemotherapy: childhood ALL as a model

  2001cites this paper
• Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.

  2000cites this paper
• Pharmacokinetics in the child.

  1994cites this paper
• TherapeuticDrugMonitoring in CancerManagement

  1993cites this paper
• Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).

  1993cites this paper
• Therapeutic drug monitoring in cancer management.

  1993cites this paper
• Adverse prognostic features in 251 children treated for acute myeloid leukemia.

  1993cites this paper
• Clinical pharmacology of cancer chemotherapy in children.

  1989cites this paper